|
|
|
|
|
|
|
13.01.26 - 01:48
|
Stocks Rise as Credit Card Shares Slip on Trump Rate Cap Talk | The Close 1/12/2026 (Bloomberg)
|
|
|
Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are Former Federal Reserve Governor Betsy Duke, GE HealthCare's Peter Arduini, CFRA's Ken Leon, Zoetis' Kristin Peck, Morgan Stanley's Lauren Hochfelder, Blackrock's Jay Jacobs, Cornell University's Eswar Prasad, PGIM's Cathy Marcus, Elanco Animal Health's Jeff Simmons, Pfizer's Albert Bourla. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
12.01.26 - 13:12
|
Vibrant Therapeutics Raises $61M and Appoints Han Lee, Ph.D. as Co-CEO (Business Wire)
|
|
|
New investors include Pfizer Ventures and Apricot Capital with proceeds to advance pipeline and global expansion
Vibrant's lead solid tumor program, VIB305, is a logic-gated, dual-targeting masked T-cell engager for EGFR-positive solid tumors and recently received US FDA IND acceptanceGUANGZHOU, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vibrant Therapeutics (“Vibrant”), a clinical-stage biotechnology company developing next-generation intelligent therapeutics, today announced $61 million in new financing. The financing includes new investors Pfizer Ventures and Apricot Capital with participation from Bayland Capital, HSG, Northern Light Venture Capital, and First Principle Venture Limited. This brings Vibrant's total capital raised to $100 million.
The company also announced the appointment of Han Lee, Ph.D., as co-chief executive officer (CEO), and the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its lead program, VIB305, for the treatment...
|
|
|
|
|
|
|
|
|
|
|
09.01.26 - 14:03
|
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor (GlobeNewswire EN)
|
|
|
CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, strengthening the company's leadership in shaping the next generation of MASH therapies and combination regimens. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inflammation in the liver....
|
|
|
09.01.26 - 03:45
|
Monsanto Sues COVID-19 Vaccine Manufacturers, Alleging Copyright Infringement (ZeroHedge)
|
|
|
Monsanto Sues COVID-19 Vaccine Manufacturers, Alleging Copyright Infringement
Authored by Zachary Stieber via The Epoch Times,
Bayer and its Monsanto division are suing COVID-19 vaccine manufacturers, alleging they used technology Monsanto developed and patented in the 1980s in their vaccines.
Bayer said in lawsuits that Pfizer, its partner BioNTech, and Moderna wrongly used technology Monsanto developed and used to make plants resistant to insects.
Pfizer-BioNTech and Moderna included the technology in their shots to enhance the stability of messenger ribonucleic acid (mRNA) “and thus the vaccines' ability to confer immunity to the virus,” lawyers for Bayer and Monsanto said in the suits, which were filed on Jan. 6 with the U.S. court in Delaware.
Bayer was not involved in COVID-19 vaccine manufacturing or production.
Bayer said it was not seeking to interfere with the production of the COVID-19 vaccines, which are still being made and sold, but said the court should award it money, desc...
|
|
|
08.01.26 - 16:03
|
Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform for Targeted Protein Degradation Enabled by Proteomics and Machine Learning (Business Wire)
|
|
|
Seed round co-led by Elaia, Pfizer Ventures and Bpifrance
Machine-learning platform enables signal peptide-informed discovery of small molecules that selectively inhibit protein secretion allowing for the degradation of disease-related proteins at the point of synthesisPARIS--(BUSINESS WIRE)--#Biotech--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has raised €20.7 million (US$25 million) in a Seed financing. The round was co-led by Elaia, Pfizer Ventures and Bpifrance, as part of the InnoBio investment strategy, with participation from Wallonie Entreprendre, Argobio Studio, MACSF, The Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital.
Enodia's proprietary discovery platform, built on Institut Pasteur science, uses machine learning to selectively modulate the SEC61 translocon, where secreted and transmembrane proteins are directed into the secretory pathway at the point o...
|
|
|
|
|
|
|
08.01.26 - 14:30
|
Pfizer Hold (DPA-AFX)
|
|
|
HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Pfizer in einem Ausblick auf die Pharmabranche 2026 auf "Hold" mit einem Kursziel von 25 US-Dollar belassen. Was die Umsätze betrifft sieht Luisa Hector laut einer am Donnerstag ......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
